Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregabalin for prevention of succinylcholine-induced fasciculation and myalgia
IRCT20160430027677N11Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of pregabalin in Succinylcholine-induced fasciculation (SIF) and Postoperative myalgia (POM) (2 arms), sponsored by Urmia University of Medical Sciences. Primary endpoint: Incidence of fasciculation. Started Nov 2016; status: completed.
02
Drugs
pregabalin
03
Conditions
Succinylcholine-induced fasciculation (SIF)Postoperative myalgia (POM)
Beyond the preview
Go deeper on IRCT20160430027677N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160430027677N11.